Dexamethasone
Brand names: Hemady, Dexamethasone, Dexamethasone Intensol, Maxidex, Ozurdex
At a glance
- Medicare prescriptions, 2024
- 994,601
- Medicare drug cost
- $13.3M
- Average cost per prescription
- $13.42
- Clinicians who prescribed it
- 29,181
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
OZURDEX is a corticosteroid indicated for: The treatment of macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO) The treatment of non-infectious uveitis affecting the posterior segment of the eye The treatment of diabetic macular edema 1.1 Retinal Vein Occlusion OZURDEX ® (dexamethasone intravitreal implant)
From the FDA-approved prescribing information (label dated March 2026). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Hematology & Oncology 25.1%
- Nurse Practitioners 14.8%
- Medical Oncology 8.5%
- Physician Assistants 7.2%
- Internal Medicine 7.2%
- Family Medicine 7.0%
- General Practice 5.3%
- Dentists (general) 5.1%
- Endocrinology & Diabetes 2.9%
- Radiation Oncology 2.0%
- Emergency Medicine 1.4%
- Orthopedic Surgery 1.2%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 55% from 2019 to 2024.
Biggest change by state since 2019
- Utah +87%
- Nevada +84%
- Oklahoma +80%
- Texas +78%
- Florida +76%
- Massachusetts (smallest change) +34%
- New York (smallest change) +36%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 1 maker on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Pd-Rx Pharmaceuticals, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 0.75 mg | gray oval tablet, 7 mm, scored to split in 2 | 1792 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
Drug makers reported $614,895 in payments to clinicians that named this drug in 2025 (meals, speaking, consulting and similar).
- AbbVie Inc. $414,356
- Ocular Therapeutix, Inc. $200,539
Source: CMS Open Payments, general payments (not research), program year 2025. A payment is not evidence of wrongdoing. Payments by doctor
Recalls and shortages
Not on the FDA drug shortage list.
No FDA-reported recalls since 2020.
Industry-funded trials
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.